all the information, none of the junk | biotech • healthcare • life sciences

San Diego Life Sciences Roundup: Evoke, Halozyme, Biocept, and More

(Page 3 of 3)

cancer stem cells as a potential treatment of glioblastoma (GBM) and other cancers. The original research was done in the lab of Santosh Kesari, who specializes in neurology and neuro-oncology. Sova Pharmaceuticals founder Gregory Stein is the founding CEO of Curtana.

—San Diego’s Sequenom (NASDAQ: SQNM) said it has hired Jefferies to review potential strategic alternatives for its genetic analysis business segment. The company said it does not plan to disclose or comment on developments regarding its review of strategic alternatives until further disclosure is deemed appropriate.

—San Diego-based Illumina (NASDAQ: ILMN) named Dr. Richard Klausner as senior vice president and Chief Medical Officer, reporting directly to CEO Jay Flatley. Illumina said Klausner will lead Illumina’s strategies for advancing genomics into clinical medicine and public health.

—Germany’s BASF acquired Verenium, the San Diego specialist in industrial enzymes, for about $62 million. Verenium holds a catalog of enzymes collected around the world, and generates more than $50 million from sales of certain enzymes that are used as industrial to make certain biochemical reactions and processes possible.

—San Diego’s Aethlon Medical said the Defense Advanced Research Projects Agency (DARPA) has exercised an option to extend work on a dialysis-like device that could be used to reduce the incidence of sepsis, a potentially fatal bloodstream infection. Aethlon said the extension would provide more than $1.5 million to advance the program.

Single PageCurrently on Page: 1 2 3 previous page